On Monday, Alkermes plc (NASDAQ:ALKS)’s shares surged 1.65% to $64.57, after an integrated biopharmaceutical company, declared that preclinical data from studies of the company’s selective effector cell activator (SECA™) immuno-oncology drug candidate, RDB 1450 (formerly referred to as RDB 1419), will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, Pa., April 18-22, 2015. Based on the preclinical data for this program to date, Alkermes plans to initiate a phase 1 clinical study of RDB 1450 in the third quarter of 2015.
The poster presentations at AACR on Alkermes’ SECA immuno-oncology program comprise:
Tuesday, April 21, 2015, 8:00 a.m. – 12:00 p.m. EDT
“Ex Vivo Expansion and Activation of Human Lymphocytes With a Selective Agonist of the Intermediate-Affinity IL-2 Receptor.” Abstract Number: 3158, Location: Poster Section 12.
Tuesday, April 21, 2015, 1:00 p.m. – 5:00 p.m. EDT
“Utilizing a Selective Agonist of the Intermediate-Affinity IL-2 Receptor With an Improved Pharmacokinetic Profile Leads to an Improved Immunostimulatory Response With Reduced Toxicity in Mice.” Abstract Number: 4280, Location: Poster Section 24.
“Determination of the Relative Potency of a Selective Agonist of the Intermediate-Affinity IL-2 Receptor on Lymphocytes from Human, Cynomolgus Monkey and Mouse.” Abstract Number: 4281, Location: Poster Section 24.
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas.
Under Armour, Inc. (NYSE:UA)’s shares gained 1.62% to $85.11, during the last trading session on Monday, as Under Armour will report the results of its first quarter ended March 31, 2015 on Tuesday, April 21, 2015 at 7:15 a.m. ET. Under Armour administration will host a conference call to talk about the results starting at 8:30 a.m. ET.
Under Armour, Inc., together with its auxiliaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company offers its apparel in compression, fitted, and loose types to be worn in hot, cold, and in between the extremes.
At the end of Monday’s trade, Patterson-UTI Energy Inc. (NASDAQ:PTEN)’s shares gained 1.62% to $20.34, after PATTERSON-UTI ENERGY, INC. (PTEN) stated that for the month of March 2015, the Company had an average of 142 drilling rigs operating in the United States and four rigs in Canada. For the three months ended March 31, 2015, the Company had an average of 165 drilling rigs operating in the United States and eight rigs in Canada.
Average drilling rigs operating stated in the Company’s monthly declarations represent the average number of the Company’s drilling rigs that were operating under a drilling contract. The Company cautioned that numerous factors in addition to average drilling rigs operating can influence the Company’s operating results and that a particular trend in the number of drilling rigs operating may or may not indicate a trend in or be indicative of the Company’s financial performance. The Company intends to continue providing monthly updates on drilling rigs operating shortly after the end of each month.
Patterson-UTI Energy, Inc., through its auxiliaries, provides onshore contract drilling services to major and independent oil and natural gas operators in the United States and Canada. The company operates through three segments: Contract Drilling, Pressure Pumping, and Oil and Natural Gas.
Finally, MEI Pharma, Inc. (NASDAQ:MEIP), ended its Monday’s trading session with 1.60% gain, and closed at $1.90, as an oncology company focused on the clinical development of novel therapies for cancer, declared recently that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 1:40 p.m. Eastern time from the Westin Grand Central Hotel in New York.
MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally accessible histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. Its clinical development pipeline also comprises ME-344, an isoflavone-derived mitochondrial inhibitor drug candidate that is in Phase Ib trial to treat lung and ovarian cancer; and PWT143, an oral inhibitor of phosphatidylinositide 3-kinase, which is in pre-clinical stage for the treatment of cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
